IDEAYA Biosciences (IDYA) Stock Overview
A precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IDYA Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
IDEAYA Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.26 |
| 52 Week High | US$32.67 |
| 52 Week Low | US$13.45 |
| Beta | 0.14 |
| 1 Month Change | 13.68% |
| 3 Month Change | 32.88% |
| 1 Year Change | -5.25% |
| 3 Year Change | 80.95% |
| 5 Year Change | 135.97% |
| Change since IPO | 161.48% |
Recent News & Updates
Recent updates
IDEAYA Biosciences: Positive Darovasertib Data In Neo-Adjuvant Melanoma Sets Next Catalyst
Sep 08We're Keeping An Eye On IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate
Jul 28
Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later
Apr 16Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth?
Apr 13Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming
Feb 10We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth
Jan 03Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash
Dec 04Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success
Sep 20Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?
Jul 08Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'
Jun 18Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?
Feb 22Ideaya Biosciences: A Strong Bet In Targeted Oncology
Feb 16Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week
Nov 09Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Oct 03IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans
Jul 04Shareholder Returns
| IDYA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.3% | 2.3% | 0.1% |
| 1Y | -5.2% | 1.4% | 14.7% |
Return vs Industry: IDYA underperformed the US Biotechs industry which returned 1.4% over the past year.
Return vs Market: IDYA underperformed the US Market which returned 14.7% over the past year.
Price Volatility
| IDYA volatility | |
|---|---|
| IDYA Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IDYA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IDYA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 131 | Yujiro Hata | www.ideayabio.com |
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor.
IDEAYA Biosciences, Inc. Fundamentals Summary
| IDYA fundamental statistics | |
|---|---|
| Market cap | US$2.56b |
| Earnings (TTM) | -US$331.80m |
| Revenue (TTM) | US$7.00m |
Is IDYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDYA income statement (TTM) | |
|---|---|
| Revenue | US$7.00m |
| Cost of Revenue | US$342.45m |
| Gross Profit | -US$335.45m |
| Other Expenses | -US$3.64m |
| Earnings | -US$331.80m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.79 |
| Gross Margin | -4,792.10% |
| Net Profit Margin | -4,740.03% |
| Debt/Equity Ratio | 0% |
How did IDYA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/20 18:46 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IDEAYA Biosciences, Inc. is covered by 33 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Peter Lawson | Barclays |
| Zhiqiang Shu | Berenberg |